4
Changes in Ownership
Xenon Pharmaceuticals Inc. Filed Acc 0000950170-24-028795
EVP, Strategy & Innovation sold 7,137 shares at an average $46.28 ($330,290)
- EVP, Strategy & Innovation acquired 8,641 shares (option exercise)
- EVP, Strategy & Innovation gave up 1,504 shares (to pay taxes)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Option exercise | +1,234 | $9.85 | $12,155 | 9,632 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Shares withheld for taxes | −215 | $45.96 | $9,881 | 9,417 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Option exercise | +7,407 | $9.85 | $72,959 | 16,824 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Shares withheld for taxes | −1,289 | $45.96 | $59,242 | 15,535 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Sale | −1,019 | $46.15 | $47,027 | 14,516 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Sale | −6,118 | $46.30 | $283,263 | 8,398 | D |
| Derivatives | |||||||
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Option exercise · Stock Option (Right to Buy) | −1,234 | 0 | D | ||
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2024-03-07 | Option exercise · Stock Option (Right to Buy) | −7,407 | 0 | D | ||
| Open-market sales · 7,137 sh · avg $46.28 · $330,290 | |||||||
Loading xslF345X05/ownership.xml…